Pharmaceutical Technology

NOVEMBER 8, 2022

Cyagen and Neurophth Therapeutics have entered a strategic partnership to jointly develop next-generation AAV gene therapy vectors for specific kinds of genetic ophthalmic ailments. Additionally, Neurophth will oversee the clinical trials and marketing of gene therapy products developed leveraging the new AAV capsids of Cyagen.

Gene Therapy 305

Gene Therapy Gene Development Genetics 305

Pharmaceutical Technology

DECEMBER 23, 2022

Eli Lilly and Company has expanded a licencing and partnership agreement with ProQR Therapeutics to discover, develop and market new genetic medicines. The post Lilly and ProQR to expand genetic medicine development agreement appeared first on Pharmaceutical Technology.

Genetics 328

Genetics Medicine Development Gene Therapy 328

Pharmaceutical Technology

MARCH 28, 2023

Following on from its Covid-19 vaccine programmes, BioNTech has set its sights on a range of infectious diseases for vaccine development. The company saw major successes with its Covid-19 vaccine, developed in collaboration with Pfizer. In response to the lower vaccine sales forecasts, BioNTech shares opened at 3.9%

Vaccine 276

Vaccine Vaccination Development Clinical Trials 276

Bio Pharma Dive

JULY 1, 2024

The gene therapy developer, which cut jobs in October, expects the sale of a Lexington, Massachusetts, facility to Genezen to lower its cash burn.

Sales 180

Sales Gene Therapy Manufacturing Gene 180

Bio Pharma Dive

MAY 21, 2024

drugmaker aims to catch up in developing new tumor-fighting technologies — areas where it has lagged behind leaders like Novartis and J&J.

Sales 260

Sales Drugs Development 260

Pharmaceutical Technology

OCTOBER 21, 2022

Hookipa Pharma and Roche have signed a strategic partnership and licence agreement for developing HB-700 and another undisclosed arenaviral immunotherapy. Under the deal, Hookipa will carry out research and initial clinical development through Phase Ib for HB-700 to treat KRAS-mutated cancers.

Development 278

Development Production Licensing Licensing 278

Bio Pharma Dive

AUGUST 6, 2024

The company plans to limit sales of the hemophilia gene therapy to the U.S., Italy and Germany, while ending most clinical development work.

Sales 173

Sales Gene Therapy Clinical Development Gene 173

Pharmaceutical Technology

JUNE 28, 2022

Astellas Pharma and Sutro Biopharma have entered a global, strategic partnership and licencing agreement to discover and develop new immunostimulatory antibody-drug conjugates (iADCs). Astellas and Sutro will expedite the development of iADCs for three different biological targets. It can potentially enhance the anti-cancer effect.

Development 264

Development Antibody Immune Response Production 264

Bio Pharma Dive

DECEMBER 13, 2023

The company is now expecting to save $4 billion by the end of 2024, with a majority of the spending cuts coming from drug research and development.

Sales 290

Sales Development Drugs Research 290

Pharmaceutical Technology

MAY 9, 2023

Ginkgo Bioworks and Boehringer Ingelheim have collaborated to develop breakthrough therapies for hard-to-treat diseases. The companies will use the natural product discovery capabilities of Ginkgo Bioworks to expedite the discovery and development of new therapeutic molecules to address diseases with high unmet patient needs.

Development 261

Development Protein Sales Production 261

Pharmaceutical Technology

APRIL 5, 2023

Austrian molecular glue degraders discovery and development company Proxygen and Merck , known as MSD outside the US and Canada, have entered into a multi-year research collaboration and licence deal. Proxygen will receive royalties on net sales of products developed under the partnership.

Development 246

Development Engineer Sales Research 246

Pharmaceutical Technology

JULY 13, 2022

Merck (MSD outside North America) and Orion have entered an international agreement to develop and market the latter’s investigational candidate ODM-208 to treat metastatic castration-resistant prostate cancer (mCRPC). Orion discovered and developed ODM-208 to treat hormone-dependent cancers, such as prostate cancer.

Development 264

Development Hormones Production Marketing 264

Pharmaceutical Technology

DECEMBER 15, 2022

Eisai has entered a comprehensive research partnership agreement with Washington University School of Medicine in St Louis, US, to develop potential new therapies for neurodegenerative ailments. Under the deal, the parties intend to develop treatments for diseases including Alzheimer’s and Parkinson’s.

Development 246

Development Medicine Sales Scientist 246

Pharmaceutical Technology

MAY 8, 2023

Ei s ai and Bliss Biopharmaceutical have entered into a joint development agreement for antibody-drug conjugate (ADC), BB-1701, to treat cancers. The collaboration will help in further development of BB-1701 across the world and advance the ADC towards late stage of development.

Development 246

Development Antibody Clinical Trials Clinical Trials 246

Pharmaceutical Technology

APRIL 20, 2023

Chinese firm Hasten Biopharmaceutic has raised $315m for business development of its pipeline assets in a financing round co-led by Singapore-based CBC Group and Abu Dhabi sovereign wealth fund Mubadala Investment, The funding round was supported by additional institutional investors.

Development 246

Development Business Development Sales Drugs 246

Pharmaceutical Technology

JANUARY 3, 2024

Novartis will pay Voyager $100m upfront and up to $1.2bn in milestone-based payments and royalties on net sales.

Gene Therapy 246

Gene Therapy Gene Development Sales 246

Bio Pharma Dive

FEBRUARY 13, 2023

The company said its modified contract with the federal government, which comes ahead of a planned transition to private market sales, will help it develop an updated version of its vaccine.

Sales 343

Sales Vaccine Vaccination Marketing 343

Pharma Mirror

JUNE 23, 2023

In the fast-paced, highly competitive pharmaceutical industry, sales reps must adapt to new ways of engaging with customers and healthcare professionals (HCPs).

Sales 130

Sales Development Marketing 130

Pharmaceutical Technology

APRIL 3, 2023

BioNTech has signed exclusive licence and collaboration agreements with Duality Biologics (DualityBio) for the development of two antibody-drug conjugate (ADC) assets for solid tumours. Once developed, the ADCs will join BioNTech’s existing portfolio of oncology products.

Development 246

Development Sales Antibody Manufacturing 246

Pharmaceutical Technology

DECEMBER 12, 2022

Gilead company Kite has entered an international strategic partnership with Arcellx for the joint development and commercialisation of the latter’s T-cell therapy, CART-ddBCMA, to treat relapsed or refractory multiple myeloma patients. Additionally, Kite will make other potential payments to Arcellx.

Development 264

Development Gene Therapy Clinical Trials Clinical Trials 264

Bio Pharma Dive

AUGUST 1, 2024

The job cuts affects 65% of UniQure’s workforce and include the gene therapy developer’s recent sale of a manufacturing plant to Genezen.

Gene Therapy 281

Gene Therapy Sales Gene Manufacturing 281

Bio Pharma Dive

DECEMBER 13, 2022

The positive data are the most significant findings for the mRNA developer’s pipeline of experimental treatments outside of infectious diseases, where it has reaped billions from COVID-19 vaccine sales.

Vaccine 315

Vaccine Vaccination Sales Development 315

Pharmaceutical Technology

JANUARY 25, 2023

It was an exceptional year for Moderna’s vaccine Spikevax, with forecast sales of $19.5bn in 2022. Currently, Spikevax is the second bestselling Covid-19 vaccine behind Pfizer’s Comirnaty, which is in the leading position, with forecast sales of $37bn in 2022.

Sales 147

Sales Vaccine Vaccination Marketing 147

Bio Pharma Dive

JULY 9, 2021

Zynteglo sales have been on hold since February, when a patient in a clinical trial of another, related Bluebird medicine developed leukemia.

Gene Therapy 271

Gene Therapy Gene Marketing Clinical Trials 271

Camargo

NOVEMBER 11, 2020

Each month, Camargo’s “In the News” series highlights important changes and advancements in the regulatory and development space and explores how those changes could impact your program. Presumably, Antares’ long-established 90-person urology sales force can achieve pull-thru of this drug product. Manager of Regulatory Compliance.

Development 242

Development Bioequivalency Generic Drugs Production 242

Bio Pharma Dive

MARCH 13, 2024

The pharma intends to test a single-dose regimen as well as a shot that may provide broader protection than the current versions of Gardasil that regularly generate billions in annual sales.

Development 187

Development Sales 187

Pharmaceutical Technology

FEBRUARY 16, 2023

Aqilion and Merck have entered an exclusive licence and strategic research partnership for the discovery, development and commercialisation of the transforming growth factor-β-activated kinase 1 (TAK1) protein-small molecule inhibitors. Aqilion will handle the design and synthesis of the new small molecule TAK1 inhibitors.

Protein 147

Protein Development Sales Business Development 147

Pharmaceutical Technology

DECEMBER 14, 2022

GSK has entered a strategic partnership with Wave Life Sciences to progress the discovery and development of oligonucleotide therapies for new genetic targets. The discovery alliance, with a preliminary research period of four years, will aid GSK in progressing up to eight programmes and Wave to develop up to three programmes.

Life Science 162

Life Science Development Gene Therapy Genetics 162

Pharmaceutical Technology

AUGUST 4, 2022

Poseida Therapeutics and Roche have signed a strategic partnership and licence agreement to develop allogeneic CAR-T cell therapies for hematologic malignancies. Roche and Poseida will also partner in a research programme for creating and developing next-generation features and enhancements for allogeneic CAR-T therapies.

Development 147

Development Clinical Trials Clinical Trials Gene Therapy 147

Bio Pharma Dive

OCTOBER 2, 2023

The divestments will bring in more than $3 billion as the company works to reduce its debt and plan for future business development.

Sales 164

Sales Business Development Drugs Development 164

Pharmaceutical Technology

SEPTEMBER 15, 2022

As a result of huge global sales of mRNA Covid-19 vaccines, the split in profits between Pfizer and BioNTech’s Comirnaty contributed towards revenues of $81.3bn and $22.4bn last year, respectively. Pfizer reaped $36.8bn from Comirnaty, the highest revenue generated from Covid-19 vaccine sales worldwide. YoY revenue growth.

Vaccine 272

Vaccine Vaccination Sales Generic Drugs 272

Pharmaceutical Technology

JUNE 12, 2023

Accordingly, the development of non-opioid painkillers is experiencing a surge in activity and despite numerous novel targets receiving high levels of attention, cannabinoids have emerged as strong favourites to replace opioid-related medications. On 9 May, National Fentanyl Awareness Day was observed in recognition of the US opioid crisis.

Drugs 358

Drugs Development Clinical Development Sales 358

World of DTC Marketing

OCTOBER 5, 2021

last year gave away more than $23 billion in rebates to insurance intermediaries, but still netted $50 billion in sales. This taxpayer support comes during the riskiest and most pivotal points in early drug discovery, whereas private funding often comes in later to support development and regulatory approval. Washington Post.

Sales 241

Sales Drugs Manufacturing Production 241

Pharmaceutical Technology

OCTOBER 7, 2022

Surrozen and Boehringer Ingelheim have entered a partnership and licence agreement for researching and developing SZN-413 to treat retinal diseases. on meeting development, regulatory and commercial milestones, apart from sales-based royalty payments. Additionally, Surrozen is entitled to get payments totalling up to $586.5m

Development 147

Development Genetics Sales Antibody 147

XTalks

NOVEMBER 21, 2024

Jeff Emmick, MD, PhD, senior vice president, product development, Lilly said, “These results underscore the critical role of long-term therapy with effective treatments like tirzepatide to achieve and maintain weight reduction.” In the third quarter of 2024, Mounjaro’s type 2 diabetes sales reached $3.11 billion in the second quarter.

Sales 105

Sales Insulin Drugs Trials 105

Pharmaceutical Technology

AUGUST 2, 2022

Sosei Heptares , a corporate brand of Sosei Group Corporation, has signed a new drug discovery partnership and option-to-license agreement with AbbVie for discovering, developing and marketing new therapies for neurological ailments. Additionally, AbbVie will make tiered royalty payments based on global product sales to Sosei Heptares.

Development 147

Development Licensing Licensing Branding 147

Pharmaceutical Technology

JULY 20, 2022

Avista Therapeutics, a University of Pittsburgh Medical Center (UPMC) spinout, has entered a collaboration with Roche for developing new AAV gene therapy vectors for eyes. Roche will also make further payments to Avista during the collaboration’s research phase and clinical, sales-based milestone and royalty payments for resulting products.

Gene Therapy 147

Gene Therapy Gene Development In-Vivo 147